Essen University Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2022

  1. Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial

    Nature Medicine, Vol. 28, Núm. 8, pp. 1640-1645

2016

  1. Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial

    Annals of Oncology, Vol. 27, Núm. 3, pp. 417-423